(UTHR) United Therapeutics Corporation BCG Matrix Research

Remunity Pump is a compact treprostinil delivery system that supports United Therapeutics Corporation’s prostacyclin franchise by keeping subcutaneous therapy easier to use and helping retain patients in a mature pulmonary arterial hypertension market.

• Supports treprostinil platform stickiness
• Helps preserve patient retention
• Bolsters market share in a mature niche
• Fits the Stars role if adoption stays strong

United Therapeutics’ treprostinil franchise spans inhaled Tyvaso/Tyvaso DPI, oral Orenitram, and infused Remodulin, giving the Company three delivery routes in prostacyclin therapy. That breadth supports scale, physician reach, and patient switching across disease stages, so the franchise stays the core growth engine into end-2025.

• Three delivery formats: inhaled, oral, infused.
• Four major brands: Tyvaso, Tyvaso DPI, Orenitram, Remodulin.
• Broadest prostacyclin platform in the portfolio.

Treprostinil renewals are a cash cow for United Therapeutics Corporation because PAH care is chronic: patients often stay on long-term maintenance therapy, so refills keep coming with little new-market spend. In 2024, United Therapeutics reported $2.8 billion in total revenue, and its treprostinil franchise stayed a core driver of that recurring cash flow. The stickiest value comes from repeat prescriptions, not one-off starts.

• Chronic PAH use drives ongoing refills
• Low incremental spend after launch
• Recurring revenue supports strong cash generation

United Therapeutics Corporation’s manufacturing and device support act like a Cash Cow because the delivery system and supply chain behind its mature prostacyclin brands keep revenue flowing after the launch costs are already sunk. That setup turns product leadership into operating cash, with far less incremental promo spend than early-stage brands.

• Supports mature prostacyclin products.
• Low extra promotion after build-out.
• Converts scale into cash flow.

United Therapeutics Corporation’s oncology footprint stays small in 2025: it has no meaningful cancer sales, while Tyvaso remains the clear growth engine and core value driver. The gap is wide, since the pulmonary hypertension franchise carries most revenue and commercial scale, but oncology is still a niche R&D bet.

• Small, non-core oncology exposure
• No material 2025 oncology revenue
• Tyvaso drives growth and cash flow

United Therapeutics Corporation’s growth story is driven by its core pulmonary hypertension franchise, so any remaining legacy commercial assets with low share and limited upside fit the Dogs bucket. These are modestly strategic and best treated as harvest-or-exit assets, not growth engines.

• Low share, weak expansion
• Outside core growth story
• Best for deemphasis

Tyvaso PERFECT is a question mark because it targets PH-COPD, a large but hard-to-win market where approval is still uncertain. COPD affects about 16 million adults in the U.S., and pulmonary hypertension in COPD can be severe, but Tyvaso PERFECT has low current share because it is still a clinical program.

• Large addressable PH-COPD pool
• Clinical risk remains high
• Share is near zero today
• Upside depends on approval

United Therapeutics Corporation’s TETON program is still a question mark in BCG terms because it is an expansion set of studies for Tyvaso in additional pulmonary hypertension settings, and the market size depends on readout success. The upside is real: if TETON widens the label, it can add new patient demand on top of Tyvaso’s large franchise, which drove a big share of United Therapeutics Corporation’s multi-billion-dollar sales base in 2025. Until trial data land, the program is value-creating but unproven.

• TETON could expand Tyvaso use.
• Label expansion may lift demand.
• Result timing still drives risk.